Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13145307 | 0.82 | ALDH1A1 (0.55) | PTGS1PTGS2GPBAR1L3MBTL1LMNA | |
| SCHEMBL10083918 | 0.80 | PTGS1 (0.66) | ATMPTGS1PTGS2HSD17B10GPBAR1 | |
| SCHEMBL10394013 | 0.80 | PTGS1 (0.66) | ATMPTGS1PTGS2HSD17B10GPBAR1 | |
| SCHEMBL12457439 | 0.78 | ALDH1A1 (0.51) | ATMPTGS1PTGS2GPBAR1L3MBTL1 | |
| SCHEMBL14258658 | 0.77 | PTGS1 (0.62) | ATMPTGS1PTGS2HSD17B10GPBAR1 | |
| SCHEMBL9967689 | 0.76 | PTGS1 (0.59) | ATMPTGS1PTGS2LMNAMAPT | |
| SCHEMBL13423095 | 0.75 | HSD17B10 (0.71) | HSD17B10GPBAR1L3MBTL1LMNAMAPT | |
| SCHEMBL256686 | 0.74 | PTGS1 (0.59) | ATMPTGS1PTGS2HSD17B10GPBAR1 | |
| SCHEMBL21119516 | 0.74 | PTGS1 (0.59) | ATMPTGS1PTGS2HSD17B10GPBAR1 | |
| SCHEMBL820838 | 0.74 | PTGS1 (0.59) | ATMPTGS1PTGS2HSD17B10GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371337-B2 | β-lactamase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20140315861-A1 | BETA-LACTAMASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-7928129-B1 | Nanomolar β-lactamase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7271186-B1 | Nanomolar β-lactamase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271186-B1 | Nanomolar β-lactamase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | ATM 4405/4885PTGS1 1155/4885PTGS2 1750/4885 |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | ATM 1485/4885PTGS1 785/4885PTGS2 1501/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | ATM 1485/4885PTGS1 785/4885PTGS2 1501/4885 |
| US-20140315861-A1 | BETA-LACTAMASE INHIBITORS | BTD, GUSB, BLVRB | ATM 2956/4885PTGS1 3372/4885PTGS2 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.